Protocol Ledger

NCT04782115 · Phase II · COMPLETED

Evaluation of RC28-E Injection in Diabetic Macular Edema

Interventional Phase II clinical trial protocol NCT04782115 sponsored by RemeGen Co in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-17 Enrollment: 156 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04782115
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)156 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04782115
Protocol FieldVerified Registry Value
NCT IdentifierNCT04782115
Consolidated Lead SponsorRemeGen Co
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment156 participants (ACTUAL)
Registered Start Date2021-03-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI